(Q37719552)

22 August 2017

1 reference

title

Patented cancer vaccines: the promising leads (English)

1 reference

22 August 2017

0 references

Gennaro Ciliberto

2

0 references

author name string

Luigi Aurisicchio

series ordinal

1

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 May 2010

1 reference

Expert Opinion on Therapeutic Patents

22 August 2017

published in

1 reference

22 August 2017

volume

20

1 reference

22 August 2017

issue

5

1 reference

22 August 2017

page(s)

647-660

1 reference

Prevention of human papillomavirus infections and associated diseases by vaccination: a new hope for global public health

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

21 January 2018

Cancer immunotherapy.

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

GM-CSF gene-modifed cancer cell immunotherapies: of mice and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

The therapeutic potential of interleukin-6 hyperagonists and antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Global emm type distribution of group A streptococci: systematic review and implications for vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Current developments in cancer vaccines and cellular immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Identification of HLA-B27-restricted cytotoxic T lymphocyte epitope from carcinoembryonic antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Carcinoembryonic antigen-based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Therapeutic breast cancer vaccines: a new strategy for early-stage disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Prospects and challenges of building a cancer vaccine targeting telomerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Prostate cancer vaccines: current status and future potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Therapeutic vaccination in chronic hepatitis B virus carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Vaccination for treatment and prevention of cancer in animal models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

21 January 2018

DC-based cancer vaccines

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Genomic analysis of metastasis reveals an essential role for RhoC

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Grb10 and active Raf-1 kinase promote Bad-dependent cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

New functions for the matrix metalloproteinases in cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

MMP11: a novel target antigen for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

The proteasome and MHC class I antigen processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Coadministration of telomerase genetic vaccine and a novel TLR9 agonist in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Characterization of a Zinc Finger Gene Disrupted by the t(15;17) in Acute Promyelocytic Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

The discovery of common recurrent transmembrane protease serine 2 (TMPRSS2)-erythroblastosis virus E26 transforming sequence (ETS) gene fusions in prostate cancer: significance and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Glycoconjugates as vaccines for cancer immunotherapy: clinical trials and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Antigen analogs/MHC complexes as specific T cell receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

SYFPEITHI: database for MHC ligands and peptide motifs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Recombinant ovine atadenovirus induces a strong and sustained T cell response against the hepatitis C virus NS3 antigen in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Chimpanzee-origin adenovirus vectors as vaccine carriers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Efficacy of severe acute respiratory syndrome vaccine based on a nonhuman primate adenovirus in the presence of immunity against human adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Frequency, proliferation, and activation of human memory T cells induced by a nonhuman adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Contrasting effects of human, canine, and hybrid adenovirus vectors on the phenotypical and functional maturation of human dendritic cells: implications for clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Porcine adenoviral vectors evade preexisting humoral immunity to adenoviruses and efficiently infect both human and murine cells in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

A novel chimpanzee serotype-based adenoviral vector as delivery tool for cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Promises and challenges for the development of Listeria monocytogenes-based immunotherapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Chitosan micro- and nanospheres: fabrication and applications for drug and DNA delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Toll-like receptor 9 (TLR9) agonists in the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Cranking the immunologic engine with chemotherapy: using context to drive tumor antigen cross-presentation towards useful antitumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Stromelysin-3 Is Induced in Tumor/Stroma Cocultures and Inactivated via a Tumor-specific and Basic Fibroblast Growth Factor-dependent Mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

Vaccine-specific local T cell reactivity in immunotherapy-associated vitiligo in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003720483

10.1517/13543771003720483

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference